Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

Inclusion Criteria:

• Stage IV or recurrent Non-Small Cell Lung Cancer patients who either have archivaltissue for genomic analysis or are willing to undergo a new biopsy to obtain tumortissue for genomic analysis. Patients whose tumor has already undergone genomicanalysis will be eligible.

• Zubrod performance status 0-2

• Life expectancy >= 3 months

• Absolute neutrophil count of > 1.5 x 10^9/L

• Platelet count > 100,000 x 10^9/L

• Serum creatinine =< 1.5 times the institutional upper limit of normal (ULN) orcalculated creatinine clearance (Cockcroft-Gault formula) of > 45 mL/min

• Serum bilirubin =< 1.5 X ULN

• Transaminases (serum glutamic oxaloacetic transaminase [SGOT] and/or serum glutamatepyruvate transaminase [SGPT]) =< 2.5 times institutional ULN and alkalinephosphatase =< 2.5 times ULN, unless patient has liver metastases and the managingphysician believes that the elevation in liver enzymes is only related to the livermetastases

• Laboratory tests should be done within 30 days of enrollment on the trial

• A biopsy of the patient's tumor for genomic profiling is required; this biopsyspecimen can be an already obtained diagnostic specimen provided the patient has notreceived systemic therapy since the biopsy has been obtained and was obtained within 60 days of trial enrollment. The biopsy material cannot be from a tumor site thathas been radiated.

• Signed informed consent that details the investigational nature of the studyaccording to institutional and federal guidelines

Exclusion Criteria:

• Patients with concurrent malignancy; patients with prior or concurrent malignancywill be allowed as long as the treating physician considers it unlikely to impactthe clinical outcome of the patient

• Serious medical illness including but not limited to uncontrolled congestive heartfailure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6months of registration, history of chronic active hepatitis or history of humanimmunodeficiency virus (HIV) or an active bacterial infection will not be eligible

• Pregnant or lactating women; female patients of child bearing potential will beinformed that if they do enroll on a therapeutic trial, based on the genomicanalyses, that they may not be able to enroll on a clinical trial if they arepregnant; all sexually active patients will be informed that patients enrolling on atherapeutic trial have to use contraceptive methods to prevent pregnancy